PTG007
Type 1 Diabetes
About PolTREG
PolTREG is a clinical-stage biotech company pioneering T-regulatory cell (TREG) therapies for autoimmune disorders, with a focus on Type 1 Diabetes (T1D) and Multiple Sclerosis (MS). Founded as a spin-off from the Medical University of Gdańsk, it boasts the most advanced pipeline of Treg cell therapies for autoimmunity and is developing next-generation engineered CAR-Tregs. The company is publicly listed on the Warsaw Stock Exchange and is constructing a significant GMP manufacturing facility to support its clinical programs and future CDMO services.
View full company profileAbout PolTREG
PolTREG is a clinical-stage biotech company pioneering T-regulatory cell (TREG) therapies for autoimmune disorders, with a focus on Type 1 Diabetes (T1D) and Multiple Sclerosis (MS). Founded as a spin-off from the Medical University of Gdańsk, it boasts the most advanced pipeline of Treg cell therapies for autoimmunity and is developing next-generation engineered CAR-Tregs. The company is publicly listed on the Warsaw Stock Exchange and is constructing a significant GMP manufacturing facility to support its clinical programs and future CDMO services.
View full company profileTherapeutic Areas
Other Type 1 Diabetes Drugs
| Drug | Company | Phase |
|---|---|---|
| eRapa | Biodexa Pharmaceuticals | Preclinical |
| ImmCelz™ | Creative Medical Technology Holdings | Clinical Trial |
| Adimune (ADi-001/002) | Aditxt | Preclinical / Early Clinical |
| BioChaperone® Lispro (THDB0206) | Adocia | Phase 3 |
| AdoShell® Islet Cell Therapy | Adocia | Preclinical |
| Undisclosed Novel Strategy | CG Scientific | Pre-clinical |
| Sotagliflozin | Lexicon Pharmaceuticals | Phase 3 |
| Stem Cell-Derived Beta Cells | BioTalentum | Pre-clinical |
| NICHE | Continuity Biosciences | Pre-clinical |
| Type I Diabetes | Genclis | Discovery |
| Inreda AP® | Inreda Diabetic | Commercial |
| iTOL-101 | iTolerance | Preclinical |